Skip to main content
Premium Trial:

Request an Annual Quote

Premaitha Inks Russian Distribution Deal for Iona Prenatal Screening Test

NEW YORK (GenomeWeb) – Premaitha Health announced today that it has signed a deal making GeNext the exclusive distributor of its Iona non-invasive prenatal screening test in Russia.

The Iona test estimates the risk of a fetus being affected by Down syndrome and other serious genetic conditions by analyzing cell-free fetal DNA from a maternal blood sample. It received CE marking about a year ago.

Under the terms of the deal, GeNext will establish a central laboratory to act as a regional hub to process test samples. In the meantime, GeNext will send samples to Premaitha’s UK laboratory for processing.

Russia "is a new territory for Premaitha and it enables us to establish a local laboratory offering routine non-invasive prenatal screening," Premaitha CEO Stephen Little said in a statement. "The Russian market has significant potential for the Iona test, and through GeNext we are extremely well placed to accelerate market penetration across the country as awareness of the benefits of the test continues to grow."

This arrangement represents the sixth Premaitha has signed with regional partners in recent months. In February, the company signed on Visional Medical to distribute Iona in India. And in January, Premaitha announced that it had signed Iona service contracts with customers in Armenia and the Republic of Moldova. 

In 2015, Adgenix became the exclusive distributor of the Iona test in France, while Antisel and Servicios Geneticos OriGen began distributing the test in Greece and Chili, respectively.

 

 

The Scan

Looking for Omicron

NPR reports that SARS-CoV-2 testing in the US has gotten better but also that some experts say more needs to be done to better track the Omicron variant.

Holmes Alleges Abuse

The Associated Press reports that Theranos' Elizabeth Holmes has testified at her wire fraud trial that her business and romantic partner abused her.

Bit More Diverse, But More to Do

While Black and Hispanic patients are more likely to participate in cancer clinical trials than previously, they are still underrepresented, according to US News & World Report.

PNAS Papers on Yeast Gene Silencing, Zika Virus Inhibition, Immunoglobulin Hypermutation

In PNAS this week: gene silencing in Saccharomyces cerevisiae, possible neuroprotective role for SHFL in a mouse model of Zika virus infection, and more.